Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Cancer Genetics' UroGenRA-Kidney Array

Premium

Cancer Genetics, a Rutherford, NJ-based provider of oncology-focused molecular testing services, recently introduced UroGenRA-Kidney, a microarray intended for kidney cancer diagnosis and subtyping.

According to the company, the test is being offered in compliance with the US Clinical Laboratory Improvement Amendment and the approval of the New York State Department of Health. CGI said that the test will be offered to clients as part of its Kidney Complete Program, a suite of tests for kidney cancer.

It claims that UroGenRA-Kidney can be used to subtype kidney cancer tissue samples among three malignant renal cell carcinoma subtypes – clear cell, papillary, and chromophobe, as well as a benign form of renal cancer, oncocytoma. The company additionally claims that the data generated by the array can be used to select the appropriate therapy based on the kidney cancer subtype.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.